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Abstract Heat shock proteins (HSP) form a heterogenous,
evolutionarily conserved group of molecules with high
sequence homology. They mainly act as intracellular
chaperones, protecting the protein structure and folding
under stress conditions. The extracellular HSP, released in
the course of damage or necrosis, play a pivotal role in the
innate and adaptive immune responses. They also take part
in many pathological processes. The aim of this review is to
update the recent developments in the field of HSP in
chronic kidney disease (CKD), in regard to three different
aspects. The first is the assessment of the role of HSP, either
positive or deleterious, in the pathogenesis of CKD and the
possibilities to influence its progression. The second is the
impact of dialysis, being a potentially modifiable stressor,
on HSP and the attempt to assess the value of these proteins
as the biocompatibility markers. The last area is that of
kidney transplantation and the potential role of HSP in the
induction of the immune tolerance in kidney recipients.
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Introduction
Stress response is one of the most evolutionarily conserved
reactions to a wide variety of unfavorable physiological or
environmental conditions. Heat shock proteins (HSP)
constitute a heterogeneous group of main players in this
defense mechanism, characteristic for both prokaryotic and
eukaryotic organisms [1]. A growing body of evidence has
expanded the role of HSP, which have long been regarded
solely as intracellular chaperones, beyond their cytoprotec-
tive function. Current knowledge has given the opportunity
to concentrate on the immunomodulatory activity of the
extracellular HSP, influencing the innate and adaptive
immune responses or various pathologies with the compo-
nent of the disturbed immunity, such as atherogenesis,
cancer, or chronic kidney disease [2].
HSP have been classified, according to their molecular
weight, into five groups: small HSP (incl. Hsp27), HSP60,
HSP70, HSP90, and HSP110. Among these, HSP60,
HSP70, and HSP90 have been studied most extensively
due to their engagement in the chaperone activity and a vast
role of extracellular forms in the immune response [3]. In
each of these groups, the two types of HSP can be found:
stress-induced isoforms (Hsp60, Hsp70, Hsp90α), as well
as those constitutively expressed and independent of the
stress conditions (Hsc70, Hsp90β).
The main goal for the chaperones, discussed widely in
recent reviews, is to preserve cell survival by maintaining
the vital functions of proteins [1, 3]. Therefore, HSP
regulate the response to any detrimental factors, including
temperature, radiation, hypoxia, toxins or infectious agents,
by controlling the three-dimensional structure of the newly
synthesized proteins, preventing their misfolding or degra-
dation. Stress response may evoke the release of HSP
outside the cell, as an effect of an active transport or a cell
disintegration due to the infection, damage, or necrosis [2].
Then the extracellular part of the HSP story begins.
The extracellular HSP in the immune system
Although the presence of the circulating HSP and the
antibodies against them has been known for more than a
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DOI 10.1007/s00467-010-1709-5decade [4, 5], there is still much controversy about the role
of the extracellular forms of these proteins. The complexity
of the potential HSP impact on the immunity may be the
effect of a variety of functions that these proteins have.
The “danger theory” [6] has placed the extracellular HSP
in the role of “danger signals”—where the molecules
become released only under pathological conditions by
the injured or necrotic cells, thus giving an explicit warning
signal to the system of the innate immunity. The response
to that danger comes from the APC (antigen presenting
cells), recognizing HSP through the conserved pattern
recognition receptors (PRR), including the Toll-like recep-
tors (TLR). That interaction subsequently triggers APC to
produce the proinflammatory cytokines and to activate the
nuclear factor (NF)-κB, thus initiating the adaptive immune
response and the presentation of antigens to the cytotoxic T
cells [7].
HSP can also stimulate the production of cytokines by
monocytes and macrophages, as well as the expression of
the adhesion molecules on the endothelial cells. The pro-
inflammatory activity of Hsp60 is certain, whereas the
ambiguous function of Hsp70, inducing both the pro-
inflammatory (IL-6, TNF-α), and anti-inflammatory (IL-
10) cytokines, may be a matter of speculation. Similarly,
Hsp90 in the in vitro investigation has stimulated IFN-γ
and IL-4 production, activating both Th1 and Th2 lympho-
cytes [8]. Large clinical studies also gave contradictory
results of either protective [9, 10] or deleterious [11] effects
of Hsp70 in the acute coronary syndrome.
HSP are also known as physiological adjuvants,
strengthening the immune response by forming the com-
plexes with antigens, also carcinogens, ready to be trans-
formed by APC [for review see 12].
Last, but not least, there exists a theory of molecular
mimicry [13, 14]. The high HSP homology among the
species may lead to the dysfunctional immune response. In
detail, the similarity of human and bacterial HSP epitopes
may trigger the same activity and initiate the production of
antibodies, primarily directed against pathogens and then,
due to the mimicry, cross-reacting with the human HSP
through TLR. In vitro experiments have shown that the
chlamydial Hsp60, similar to that in humans, could induce
IL-6 overproduction and the adhesion molecule overex-
pression on the endothelium, smooth muscle cells, and
macrophages [15]. The additional proinflammatory and
detrimental activity, observed in mice, was the result of the
formation of the HSP-anti-HSP complexes within the
endothelial and smooth muscle cells [16]. Contrarily, the
low anti-Hsp60 and anti-Hsp70 levels in humans seem to
act as negative prognostic factors, because they were
connected with the increased risk of the acute coronary
syndrome, whereas the highest values of these anti-HSP
were observed in the healthy subjects [10, 11]. Those
discrepancies strongly suggest that the net effect of the HSP
activity is the result of a balance and a negative
biofeedback created between HSP and anti-HSP. Therefore,
the increased HSP may trigger the production of the
antibodies that, in turn, would create the HSP-anti-HSP
complexes, thus eliminating the excessive circulating
forms. The presence of such interactions was proved in
the case of the Hsp60 – anti-Hsp60 and Hsp70 – anti-
Hsp70 couples [10, 11].
HSP in chronic kidney disease (CKD)
CKD, due to the complexity of the underlying disturbances
and the variety of complications, seems an ideal example of
the cell and organ responses to the long-lasting multifacto-
rial stress conditions. The potential components of this
“stress cocktail” are: the uremic toxins, mediators of
inflammation, reactive oxygen species, apoptosis, infec-
tions, and, finally, the dialysis itself. Therefore, the
discussion about the role of HSP in chronic kidney disease
should be conducted in two parallel directions. The first one
is connected with the process of chronic renal damage and
the possible impact of HSP, either protective or deleterious,
on its progression. Secondly, it is a question of defining the
role of HSP in the possible therapeutic interventions, such
as the modification in the biocompatibility of dialysis
materials or the transplantation procedures, and the future
perspectives in optimizing the renal replacement therapy
and improving the patients’ outcome.
HSP in the progression of chronic kidney disease
The in vitro investigation performed in the late 1990s has
shown increased Hsp72 expression in human neuroblasto-
ma cells treated with urea at the concentrations ranging
from 40 to 200 mg/dl. The HSP values rose after 30 min,
obtained their peak after 10 h, and returned to zero after 48
h[ 17]. A similar experiment with creatinine at high
concentrations (0.5–14 mg/dl) had no impact on the
Hsp72 expression. This was the proof for the selective
influence of uremic toxins on the stress response and a
suggestion that the increase of Hsp72 expression may
protect against apoptosis and adapt the cell to the noxious
conditions. However, the short duration of the experiment
(only hours) could not exactly mimic the conditions
characteristic for chronic damage of the kidney. Therefore,
the interpretation of the adaptive response in the course of
CKD must be cautious. Similarly, the well-documented
anti-apoptotic and protective role of Hsp27, Hsp72, and
Hsp90 in the ischemia-reperfusion injury clearly shows the
dynamic adaptive changes after kidney transplantation
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during the long-time multifactorial CKD-related stress
[18–20].
The only data concerning the impact of HSP on chronic
kidney damage are those of Mao et al., who examined rats
with obstructive nephropathy [21]. The selective activator
of Hsp72, given orally, inhibited the proliferation and
apoptosis in tubular cells, and diminished the accumulation
of fibroblasts and collagen I in renal parenchyma, thus
slowing the process of fibrosis.
On the other hand, Lin et al. [22] have shown the
decreased expression of Hsp27 in the aortas of rats
undergoing subtotal nephrectomy. This deficiency was
most evident in the advanced atherosclerotic lesions, thus
confirming the potentially cytoprotective role of this HSP
and its impact on atherogenesis.
Contrarily, the investigation of mice with rapidly
progressive glomerulonephritis has proven the detrimental
impact of HSP on renal function. The Hsp60 injection
provoked a dramatic worsening of kidney function,
glomerular necrosis, and anuria [23]. There are no
experimental data on the role of Hsp90 in chronic kidney
disease.
Research on HSP in humans with CKD treated conser-
vatively is limited to two studies. The first one [24] has
described decreased Hsp72 expression in the peripheral
blood monocytes from the adult patients, thus suggesting
the exhaustion of the adaptive mechanisms, concordant
with the aggravated apoptosis and the impaired immunity
characteristic for CKD. The unchanged serum concentra-
tions of Hsp70 in children with CKD [25] could speak in
favor of the adaptive processes as being better preserved,
but the concomitant decrease of anti-Hsp70, a negative
prognostic factor in the cardiovascular complications,
seems to confirm the increased risk for atherosclerosis in
the course of CKD. The same study revealed diminished
serum concentrations of Hsp60 and the increased values of
anti-Hsp60. Although the low Hsp60 values in the light of
previously mentioned studies seem profitable, it is difficult
to regard them as so, if at the same time they are lower than
in the control group. The probable explanation is the
balance between HSP and anti-HSP that has been moved
towards anti-Hsp60 with the consequence of the Hsp60
inhibition and decrease of its pool. Moreover, there is no
doubt that the serum anti-Hsp60 acts negatively, accelerat-
ing the development of atherosclerosis. The elevated
Hsp90α concentrations in the same group may indicate an
enhanced oxidative stress and inflammation, which are
characteristic for CKD and trigger atherogenesis. The
correlations between Hsp90α, anti-Hsp60, and sE-selectin,
the marker of endothelial activation in children with CKD,
also suggest a role of HSP in the development of
atherosclerosis [25].
HSP in the patients on dialysis
Contrary to the scarce data concerning HSP in CKD
patients on conservative treatment, much more has been
done in the field of dialysis. The data have focused mainly
on the role of HSP as the potential markers of the
biocompatibility of materials that are used, although recent
investigations seem to reveal a new trend towards pharma-
cologic interventions potentiating the protective abilities of
HSP. However, the fact that patients on dialysis are at a
greater risk of developing cardiovascular complications
than those in a pre-dialysis state should also be taken into
account while searching for the connections between HSP
and dialysis modalities.
HSP in hemodialysis (HD)
The studies of HSP in hemodialysis have concentrated
mainly on Hsp72. It has been shown that, in regard to the
peripheral blood monocytes, the mRNA amount in adults
on HD was significantly lower than in the controls [24].
When macrophages were analyzed, no such difference was
observed in baseline Hsp72 expression, but response to
induction by the high temperature (exposure to 47°C for 40
min) was impaired and accompanied by increased apoptosis
[26]. Interestingly, the exposure of the urea-treated
(150 mg/dl) macrophages, harvested from the healthy
controls, to heat stress (47°C for 40 min) resulted in a
greater increase of Hsp72 expression than after the
incubation with urea only. This could be the indirect proof
of the previously mentioned results, when the high urea
concentrations induced Hsp72 in human neuroblastoma
cells [17]. On the other hand, it suggests that the stress
response, although altered in CKD, is not entirely abol-
ished. These results seem concordant with those of Crowe
et al. who analyzed the role of HSP in skeletal muscle
atrophy typical for patients on hemodialysis [27]. The
analysis of muscle biopsies revealed increased content of
Hsp27 and a tendency towards higher values of Hsp60 and
Hsp70, probably being an adaptive response to the stress
conditions evoked by dialysis.
The study performed in children and young adults
revealed no difference in the Hsp70 and anti-Hsp70 serum
concentrations between the subjects on hemodialysis and
controls, thus questioning the negative impact of dialysis on
the Hsp70 function in the pediatric population [28].
Although the Hsp60 values in the HD patients were
decreased, they did not differ from those in the pre-
dialysis patients, which was similar to the situation
observed in the case of Hsp70. The only exceptions were
the levels of Hsp90α and anti-Hsp60, significantly higher
in the HD subjects than in both controls and the pre-dialysis
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oxidative stress and chronic inflammation undergoing
aggravation due to dialysis. The increased anti-Hsp60
values point at the activation of the immune response,
taking place in the course of HD. Taking into account the
observed inverse correlation between Hsp60 and anti-
Hsp60, the increased concentrations of the latter may also
be responsible for the Hsp60 suppression.
The two studies, assessing the impact of a single dialysis
session with the polysulfone membranes on HSP, have
revealed an increase of Hsp72 expression [29], high Hsp60,
as well as decreased anti-Hsp60 and anti-Hsp70 concen-
trations after HD [28]. The Hsp70 activation seems
indicative of a reaction to the stressful conditions, such as
the blood-dialyzer contact. The Hsp60 increase could also be
the result of a protein release from the activated or damaged
cells after their contact with the dialyzer membrane.
Contrarily, there are many possible reasons for the decrease
in the antibody levels. Indeed, the adsorption to the
membrane surface, the creation of the HSP – anti-HSP
complexes and the elimination with the dialysis solution
have to be taken into account as probable explanations.
However, the clinical interpretation based on a single study
seems risky. While the decrease of the autoimmune activity
may be profitable, the diminished concentrations of the
antibodies would neglect the protective impact of anti-HSP
on the cardiovascular system. On the other hand, the total
cholesterol and the HDL-cholesterol levels predicted the
anti-Hsp60 concentrations both before and after a single HD
session, suggesting the relation of that antibody with the
atherosclerosis development in this group of patients [28].
Therefore, the authoritarian defining of the role of Hsp60 and
anti-Hsp60 is currently impossible, not only because of the
HSP-antiHSP interactions but also due to their ambiguous
function [30]. However, the above-mentioned results indicate
the role of hemodialysis in aggravating the HSP disturban-
ces, probably influencing atherogenesis and as is already
seen in children with CKD on conservative treatment [25].
HSP in peritoneal dialysis
The investigations of HSP in peritoneal dialysis have
mainly focused on the impact of the peritoneal fluid, as a
stressor, on the function of the peritoneum. The induction
of the Hsp72 expression has been confirmed in both
mesothelial cells incubated with the dialysis fluid [31] and
in macrophages from the dialysis effluent collected after a
4-h dwell [32]. In the meantime, the susceptibility of this
protein to the fluid content has been proven, thus pointing
to Hsp72 as a possible marker of the peritoneal fluid
biocompatibility [32, 33]. Endemann et al. [34] went further
and proved the role for HSP in the stabilization of the
cytoskeleton of mesothelial cells exposed to the peritoneal
dialysis solution (PDS). Indeed, the in vitro exposure of
human mesothelial cells to PDS resulted in the over-
expression and the shift of Hsp27 and Hsp72 from the
noncytoskeletal to the cytoskeletal fraction within the cells.
The incubation of the cytoskeletal protein, ezrin, with the
recombinant Hsp72, stabilized this protein within the
cytoskeletal fraction, whereas anti-Hsp72 caused its shift
to the nonskeletal fraction. Moreover, the Hsp72 over-
expression was predominant in the mesothelial cells
detached after the exposure to PDS. Finally, the pretreat-
ment of mesothelial cells with hyperthermia caused the
upregulation of Hsp72 and reduced detachment after the
contact with PDS.
The newest findings are these of Bender et al. [35] who
successfully improved the status of mesothelial cells by the
in vitro pharmacologic manipulation of the PDS content. In
detail, the solution enriched in glutamine improved the
viability of human mesothelial cells by inducing Hsp27 and
Hsp72 expression. In the in vivo rat model, the same
solution reduced the detachment of mesothelial cells and,
what is more, decreased the amount of the protein that was
lost with PDS.
The only study on extracellular HSP concerns children
treated with automated peritoneal dialysis (APD) [25]. The
serum concentrations of Hsp60 and anti-Hsp70 were
diminished, whereas those of Hsp90α and anti-Hsp60 were
increased in comparison to the controls. When the APD
children and the patients with pre-dialysis CKD were
compared, the first ones had significantly higher Hsp90α
and anti-Hsp60 values, thus confirming the impact of
dialysis on aggravating oxidative stress and autoimmune
reactions. However, due to the fact that there were no such
differences in the case of Hsp60 and anti-Hsp70, it is
difficult to give an accurate opinion on the influence of
APD on the quality of stress response in children.
An effort has also been made to answer the question as
to whether there is any difference between hemodialysis
and peritoneal dialysis, in regard to HSP. When the children
treated with both modalities were compared, it appeared
that the Hsp60 and Hsp90α concentrations were similar in
both groups [36]. Contrarily, the values of anti-Hsp60 in the
HD population were significantly higher than those in the
APDs, thus confirming the previously suggested negative
impact of hemodialysis, in comparison to peritoneal
dialysis, on the stress response in children. The anti-
Hsp70 values, although higher in HD than in APD,
remained unchanged versus the control group, so the
interpretation of a negative impact of hemodialysis, based
on this result, seems questionable. The possible explanation
for the unchanged anti-Hsp70 values might be the inhibi-
tion by Hsp70, overexpressed in the course of a hemodi-
alysis session [29].
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ofthe HSP responsetostressful conditions, showing thatanti-
HSP might differentiate between the two dialysis modalities
and become useful markers of biocompatibility. Although the
HSP disturbances were more evident in the case of hemodi-
alysis, this does not justify an explicitly negative opinion on
that method, in regard to the impact on the stress response, in
comparison to peritoneal dialysis. However, it may suggest
that in children with end-stage renal disease, put in the
majority of cases into peritoneal dialysis, such choice is less
harmful than hemodialysis.
HSP in kidney transplantation
The transplanted kidney undergoes ischemia-reperfusion injury
and HSP seem to play an essential role in that process. The
investigation of rat renal cortex after ischemia has revealed the
influence of overexpressed Hsp25, Hsp70, and Hsp90 on its
repair by the relocation of the Na,K-ATPase from the apical to
the basolateral membrane domain of the proximal tubule cells
[18]. The results were confirmed by the fact that anti-HSP
inhibited the translocation. Interestingly, the stabilizing power
of HSP towards Na,K-ATPase was most efficient when all
three of the HSP mentioned above acted together, suggesting
that “the HSP cocktail” is more potent than any HSP alone.
Surprisingly, another animal study by Fekete et al. has shown
that, due to the elevated Hsp72 expression and the higher Na,
K-ATPase activity, female rats are more resistant to the
ischemic changes in the kidney than are male rats [37].
The study in children after kidney transplantation has
suggested that the urinary excretion of Hsp72 is characteristic
only for the early post-transplant period, whereas the patients
with stable grafts do not have detectable levels of this HSP in
the urine [38]. They have also proven that the urine Hsp72 is
a good marker for loss of tubular cell integrity.
However, the essential concern for HSP in the organ
transplantation is their potential role in preventing or
delaying the process of rejection. The experimental data
have shown that due to heat shock proteins, the cells pre-
conditioned with sublethal stress become resistant and
survive the subsequent, otherwise lethal, unfavorable
stimulus. The natural consequence of such results was the
question of whether the stimulation of HSP in the trans-
planted kidney would ameliorate the patient’s outcome, and
preserve the kidney function for a longer time or induce
tolerance. Unfortunately, the results were ambiguous. The
stress-induced Hsp70 overexpression improved the survival
of the transplanted kidneys in both humans and rats [39,
40], whereas other experiments have shown that the Hsp70
expression has remained unchanged since the kidney
engraftment until a few months after transplantation,
irrespective of the graft function [41]. Contrarily, the
Hsp27 mRNA levels were significantly reduced in the rats
with chronic allograft nephropathy, thus suggesting the
potential profit coming from stimulating this HSP [42]. The
observed translocation of Hsp27 from the medulla to the
cortex seemed an adaptive response to the ischemic
conditions. However, the possible consequences of the
activation of such nonspecific agents as HSP might have
been unpredictable and not necessarily profitable, like the
increased immunogenicity [for review see 43].
Anotherperspectivefortherapeuticoptionsprobablyliesin
the blockade of TLR signaling, closely related to the HSP
activity, which has recently been accused of contributing to
chronic graft dysfunction [44]. The latter also suggests that
the nearest future in the HSP research should concentrate on
the interactions between these proteins, on the novel methods
of their visualization in vivo [45, 46], as well as on the
signaling pathways strictly connected with them.
Conclusions
Knowledge of the HSP engagement in chronic kidney disease
is still increasing, although not all aspects of their role in this
process are entirely understood. The intracellular forms of
HSP, with Hsp70 above all, delay the progression of CKD by
the anti-apoptotic activity and cytoprotection. The extracellu-
lar HSP in CKD show more variability in their activity,
because they may actively protect against stress conditions
(Hsp27, Hsp70), act detrimentally (Hsp60, anti-Hsp60), or be
treated merely as the indicators of the accomplished cell
damage (Hsp90α). There is no doubt that dialysis aggravates
the disturbances in stress response and the evidence points
towards hemodialysis as a more deleterious technique.
Preliminary data on the induction of protective HSP over-
expression, resulting in the increased biocompatibility of
dialysis fluids or better survival of the graft, give hope for the
successful therapeutic interventions. Therefore, future inves-
tigation should concentrate on specifying the methods of HSP
induction, thus improving the quality of renal replacement
therapy in all its facets.
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